An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease by Clark, Christopher et al.








An integrative multi-omics approach reveals new central nervous system
pathway alterations in Alzheimer’s disease
Clark, Christopher ; Dayon, Loïc ; Masoodi, Mojgan ; Bowman, Gene L ; Popp, Julius
Abstract: BACKGROUND Multiple pathophysiological processes have been described in Alzheimer’s
disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifes-
tation and disease progression remain poorly understood. We hypothesize that specific molecular patterns
indicating both known and yet unidentified pathway alterations are associated with distinct aspects of AD
pathology. METHODS We performed multi-level cerebrospinal fluid (CSF) omics in a well-characterized
cohort of older adults with normal cognition, mild cognitive impairment, and mild dementia. Proteomics,
metabolomics, lipidomics, one-carbon metabolism, and neuroinflammation related molecules were ana-
lyzed at single-omic level with correlation and regression approaches. Multi-omics factor analysis was
used to integrate all biological levels. Identified analytes were used to construct best predictive models of
the presence of AD pathology and of cognitive decline with multifactorial regression analysis. Pathway en-
richment analysis identified pathway alterations in AD. RESULTS Multi-omics integration identified five
major dimensions of heterogeneity explaining the variance within the cohort and differentially associated
with AD. Further analysis exposed multiple interactions between single ’omics modalities and distinct
multi-omics molecular signatures differentially related to amyloid pathology, neuronal injury, and tau hy-
perphosphorylation. Enrichment pathway analysis revealed overrepresentation of the hemostasis, immune
response, and extracellular matrix signaling pathways in association with AD. Finally, combinations of
four molecules improved prediction of both AD (protein 14-3-3 zeta/delta, clusterin, interleukin-15, and
transgelin-2) and cognitive decline (protein 14-3-3 zeta/delta, clusterin, cholesteryl ester 27:1 16:0 and
monocyte chemoattractant protein-1). CONCLUSIONS Applying an integrative multi-omics approach
we report novel molecular and pathways alterations associated with AD pathology. These findings are
relevant for the development of personalized diagnosis and treatment approaches in AD.
DOI: https://doi.org/10.1186/s13195-021-00814-7






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Clark, Christopher; Dayon, Loïc; Masoodi, Mojgan; Bowman, Gene L; Popp, Julius (2021). An integra-
tive multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease.




An integrative multi-omics approach
reveals new central nervous system
pathway alterations in Alzheimer’s disease
Christopher Clark1, Loïc Dayon2,3,4, Mojgan Masoodi2,5, Gene L. Bowman2,6 and Julius Popp7,8*
Abstract
Background: Multiple pathophysiological processes have been described in Alzheimer’s disease (AD). Their inter-
individual variations, complex interrelations, and relevance for clinical manifestation and disease progression remain
poorly understood. We hypothesize that specific molecular patterns indicating both known and yet unidentified
pathway alterations are associated with distinct aspects of AD pathology.
Methods: We performed multi-level cerebrospinal fluid (CSF) omics in a well-characterized cohort of older adults
with normal cognition, mild cognitive impairment, and mild dementia. Proteomics, metabolomics, lipidomics, one-
carbon metabolism, and neuroinflammation related molecules were analyzed at single-omic level with correlation
and regression approaches. Multi-omics factor analysis was used to integrate all biological levels. Identified analytes
were used to construct best predictive models of the presence of AD pathology and of cognitive decline with
multifactorial regression analysis. Pathway enrichment analysis identified pathway alterations in AD.
Results: Multi-omics integration identified five major dimensions of heterogeneity explaining the variance within
the cohort and differentially associated with AD. Further analysis exposed multiple interactions between single
‘omics modalities and distinct multi-omics molecular signatures differentially related to amyloid pathology, neuronal
injury, and tau hyperphosphorylation. Enrichment pathway analysis revealed overrepresentation of the hemostasis,
immune response, and extracellular matrix signaling pathways in association with AD. Finally, combinations of four
molecules improved prediction of both AD (protein 14-3-3 zeta/delta, clusterin, interleukin-15, and transgelin-2) and
cognitive decline (protein 14-3-3 zeta/delta, clusterin, cholesteryl ester 27:1 16:0 and monocyte chemoattractant
protein-1).
Conclusions: Applying an integrative multi-omics approach we report novel molecular and pathways alterations
associated with AD pathology. These findings are relevant for the development of personalized diagnosis and
treatment approaches in AD.
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Background
Along with amyloid pathology and tau-related neurode-
generation, multiple other molecular alterations and path-
way dysregulations have been reported in Alzheimer’s
disease (AD). Indeed, there is strong evidence that patho-
physiological changes involving neuroinflammation [1]
lipid metabolism [2], one-carbon metabolism [3], amino
acids [4], and glucose metabolism [5], among others, are
present in AD. However, the contribution and relevance
of these alterations to clinical manifestation and progres-
sion of the disease as well as their inter-individual varia-
tions, and complex interrelations, remain poorly
understood. While these processes are generally not con-
sidered part of the “core” AD pathology, they may sub-
stantially contribute to the development of amyloid
pathology and neurodegeneration and precipitate the
manifestation of symptoms. As they may be occurring at
early clinical and preclinical disease stages, a better under-
standing of these processes may be highly relevant for
both early diagnosis and prognosis and the design of tar-
geted interventions to interfere with developing AD path-
ology and clinical disease progression.
‘Omics approaches and technologies have made major
progress over the past decade to resolve the complexity
of the metabolome, lipidome and proteome [6]. As
powerful phenotyping technologies, ‘omics significantly
accelerate the understanding of mechanisms of patho-
physiological alterations that underlie complex diseases
such as AD [7, 8]. Beyond the potential of identifying al-
tered biofluid molecule profiles that could be used as
biomarkers, these technological advances also offer the
opportunity to explore different types of molecules in
parallel by combining multiple ‘omics methods. Recent
statistical advances have made it possible to integrate
the information from multiple data modalities for a
thorough exploration of endophenotype networks and
biological interactions related to disease [9]. While
multi-omics approaches have recently shown their po-
tential in relation to different other pathological condi-
tions [10–12], these methods still need to be more
broadly adapted and applied in AD [13].
Here, we hypothesized that specific patterns of pro-
teins, lipids, neuroinflammatory markers, and metabo-
lites are associated with core features of the AD
pathology and indicate disease-related, inter-connected
biological pathway alterations. We investigated these al-
terations across multiple biochemical pathways by using
a multi-layer dataset acquired by analysis of cerebro-
spinal fluid (CSF) from a cohort of elder subjects with
normal cognition. In order to integrate data from differ-
ent ‘omics platforms in an unbiased fashion while con-
sidering interactions between modalities, we combined
different approaches including single ‘omics analysis and
multi-omics factor analysis (MOFA) [14–16].
Methods
Study population
One hundred and twenty community dwelling individ-
uals, aged 55 or older, including subjects with normal
cognition, mild cognitive impairment (MCI), or mild AD
dementia (defined as previously described [3]), were en-
rolled into a brain aging study conducted in the Depart-
ment of Psychiatry and the Department of Clinical
Neurosciences, University Hospital of Lausanne,
Switzerland. They were recruited among memory clinic
outpatients or through advertisement. An overall clin-
ical, neurological, and comprehensive neuropsycho-
logical assessment was performed between 2013 and
2016, which included the Mini Mental State Examin-
ation (MMSE, [17]) and Clinical Dementia Rating (CDR,
[18]). Candidates with unstable medical conditions or
with neurological or psychiatric diseases that could
interfere with cognitive performance were excluded as
previously described [19]. Clinical and neuropsycho-
logical follow-up evaluations were performed at 18 and
36months using the same methods and tests.
Study procedures
Clinical assessment
We determined Mini-Mental State Examination (MMSE),
CDR, and CDR sum of boxes (CDR-SoB), for all partici-
pants. CDR-SoB and CDR were based on the information
available from the participant and his/her relative, the
clinical examination, and comprehensive neuropsycho-
logical test performance, as previously described [19].
Biochemical sample collection and handling
Ten to 12ml of cerebrospinal fluid (CSF) obtained from
lumbar punctures conducted after an overnight fast at
participant inclusion were spun down at 4 °C, immedi-
ately aliquoted, and snap frozen at − 80 °C until assayed
[19], with no freeze-thaw cycles allowed. Samples were
stored for a maximum of 3 years before analysis. Study
personnel blinded to clinical data performed biochemical
and genetic analyses.
Cerebrospinal fluid AD biomarkers
CSF beta-amyloid 1-42 (Aβ1-42), total-tau (Tau), and tau
phosphorylated at threonine 181 (P-Tau) concentrations
were measured using commercially available ELISA kits
(Fujirebio, Gent, Belgium) in all samples within the cohort.
Analyte measurements
Multiple ‘omics data from different pathways and vari-
ous biological levels were acquired from a vast majority
of participants within the cohort (n = 114/120 for prote-
omics, 118 for metabolomics, 119 for neuroinflammation
and one-carbon metabolism, and 120 for lipidomics).
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CSF samples were measured using an untargeted shot-
gun proteomic workflow based on liquid chromatog-
raphy (LC) tandem MS (MS/MS) using an Ultimate
3000 RSLC nano system and a hybrid linear ion trap-
Orbitrap (LTQ-OT) Elite (Thermo Scientific, San Jose,
CA, USA) [20, 21]. Relative quantification of proteins
between the samples was obtained using isobaric tagging
with the tandem mass tag technology [22]. Full experi-
mental details and parameters of the proteomic analysis
have been published previously [23, 24]. A targeted sub-
set of thirty-seven CSF inflammatory proteins including
IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, TNFα,
IL-1α, IL-5, IL-7, IL-12/23p40, IL-15, IL-16, IL-17A,
TNFβ, VEGFA, Eotaxin, MIP-1β, Eotaxin-3, TARC, IP-
10, MIP-1α, MCP-1, MDC, MCP-4, VEGF-C, VEGF-D,
Tie-2, sFLT-1 (VEGFR-1), PIGF-1R, bFGF, SAA1, CRP,
sVCAM-1, and sICAM-1 were separately quantified
using a sandwich immunoassay (Meso Scale Diagnostics
(MSD), Rockville, MD, USA), according to the manufac-
turer’s instructions. This platform has been validated by
the manufacturer (https://www.mesoscale.com/~/media/
files/product%20inserts/neuroinflammation%20panel%2
01%20human%20insert.pdf) and has been previously
used successfully [25].
CSF lipids were quantified using an MS-based shotgun
approach [26]. This technology can cover 22 quantifiable
different lipid classes encompassing more than 200 lipid
species; it achieves absolute quantification, by inclusion
of internal standards for every lipid class measured.
Figure-of-merits are an average coefficient of variation
of < 10% (intra-day), approximatively 10% (inter-day),
and approximatively 15% (inter-site) for most lipid
species.
Metabolomic profiling was carried out by means of 1H
NMR spectroscopy, as reported previously [27]. This ap-
proach covered major metabolic pathways, including
amino acids, carboxylic acids, and central energy metab-
olism. Metabolites within the one-carbon pathway are a
hypothesis-driven subset of metabolites [3] and were
separately analyzed using LC-MS/MS as previously de-
scribed [28] with an Accela UHPLC 1250 Pump coupled
to a TSQ Quantum Vantage triple quadrupole mass
spectrometer equipped with a heated electrospray
ionization source (Thermo Scientific). Selected reaction
monitoring transitions have been described previously
[28].
The initial number of analytes measured in CSF, the
final number of analytes selected per platform (a total of
891 analytes covered), and quantification method used
for each platform are summarized in Table 1.
Genetic measures
The APOE genotype was determined by PCR as previ-
ously described [29]. Participants with one or more e4
alleles were classified as carriers.
Data preparation and transformation
Lipidomics
Twenty-six high-quality intact lipids with less than 5% of
null values were selected as continuous numerical
markers from 65 original measurements. Numerical lipid
marker values were log10-transformed prior to analysis.
Metabolomics
Seventy-one peak integrals were originally measured in
CSF. Sixty-three analytes with less than 5% missing
values were selected from the obtained spectra. Peak in-
tegral values were log10-transformed prior to analysis.
One-carbon metabolomics
Seventeen analytes were initially measured in CSF. Some
analytes could not be measured in the majority of sam-
ples and were excluded from the analysis (i.e., homocys-
teic acid, dimethylglycine, betaine, total homocysteine,
pyridoxine, and pyridoxamine); taurine and glycine data
were inconsistent and were also filtered out resulting in
9 measured analytes (i.e., choline, cystathionine,
methionine, riboflavin, S-adenosylhomocysteine, S-
adenosylmethionine, serine, cysteine and 5-
methyltetrahydrofolate). Analytes with more than 5%
missing data points were also removed. Numerical
values were log10-transformed prior to analysis.
Table 1 Datasets used in this study
Dataset Analytes initial/final Quantification technique References
Proteomics 791/768 LC-MS/MS [23, 24]
Neuroinflammation 38/21 Multi-array sandwich immunoassay [29–31]
One-carbon metabolism 17/9 LC-MS/MS [28, 32]
Metabolomics 71/63 1H NMR [27]
Lipidomics 65/26 MS [26, 33]
Biomarkers of core AD pathology 3/3 ELISA [30]
Available datasets from the cohort along with the number of analytes measured in this study and the associated quantification methods. For each dataset the
initial number of analytes quantified, the number of measurements remaining after quality control, quantification technique used, and technical references are
indicated. LC-MS/MS, liquid chromatography tandem mass spectrometry; 1H NMR, proton nuclear magnetic resonance; MS, mass spectrometry; ELISA, enzyme-
linked immunosorbent assay
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Neuroinflammatory markers
Thirty-eight markers were measured in CSF. Calibration
curves, batch effects, and analytes with more than 5%
missing data points were removed, and lower limit of
quantification was controlled. After this quality control,
17 markers were removed, resulting in 21 markers se-
lected. Concentrations were log10-transformed prior to
analysis.
Proteomics
Relative quantification data were available for all subject
samples as log2 ratios as previously described [24]. Ana-
lytes with more than 5% missing data points were re-
moved, resulting in 768 proteins measured from an
initial number of 791.
Before analysis, outliers (i.e., data points that exceeded
the cutoff value of mean ± 3 × standard deviation) were
replaced by the cutoff value in all datasets (n = 28 for
lipidomics, 36 for metabolomics, none for one-carbon
metabolomics, 17 for neuroinflammatory markers, and
345 for proteomics). For all datasets, this represented
below 1% of all data points. Missing values were re-
placed using an iterative Markov chain Monte Carlo
method before single-modality feature selection ap-
proaches, but were not replaced for multi-omics analysis
as the MOFA method can handle large proportions of
missing values [14].
Statistical and analytical approaches
Descriptive statistics for the cohort were performed
using t tests comparing AD and control groups for con-
tinuous variables and chi-square tests for categorical var-
iables. Data was clustered by hierarchical clustering
across samples and factors values or loadings.
Feature selection methods
Single-modality approaches To overcome the bias
resulting from correlation between variables and thus
unreliability and saturation of standard regression tech-
niques, we used Elastic-Net regularization (α = 0.5) for
regression analysis. This was performed separately for
each individual ‘omics platform in the whole cohort
using R software with custom routines implementing the
glmnet package [34]. Each pre-specified CSF biomarker
endpoint was considered as a continuous dependent
variable and associated features were identified using a
value of λ (lambda) that minimized the 10-fold cross val-
idated error.
Multi-omics factor analysis This analysis was per-
formed using the MOFA package on the whole cohort
in R and Python software [14]. Latent factors (also re-
ferred as LFs) were selected to explain a minimum of 2%
variance in at least one data type. The MOFA model
was trained over 938 iterations with a convergence
threshold of 0.1. Individual analytes were selected if their
normalized absolute loading value was > 0.8 within any
given LF in order to include only analytes with strong
associations. More details about the MOFA method can
be found in Additional file 1. The trained MOFA model
was validated using both a correlation approach and
CSF AD biomarker predictions (Additional file 2, Figures
S1 and S2, respectively).
Associations with CSF biomarkers of AD In order to
evaluate the correlations of the analytes identified by the
MOFA model with CSF biomarkers of AD (CSF Aβ1-42,
Tau and P-Tau), we used two-tailed Spearman’s rho.
Benjamini-Hochberg correction of P value for multiple
testing was then applied using a false-discovery rate of
0.1.
Models for the prediction of AD and of cognitive
decline Predictions were ran using the glm package in
R. Subjects were classified as controls or AD, according
to the presence or absence of an AD CSF biomarker
profile, defined by a CSF P-Tau/Aβ1-42 ratio > 0.0779
based on center data [30]. We constructed a reference
model including the following covariates for AD predic-
tion: age, sex, years of education, baseline MMSE score,
and APOE4 carrier status. MMSE change at last avail-
able follow-up for one hundred and three participants,
with nineteen participants followed up at 18 months
only, and eighty-four at 36 months, was used to classify
participants with decreased global cognition as follows:
MMSE score at baseline – MMSE at last follow-up visit
≥ 2. Another reference model including age, sex, years of
education, baseline MMSE score, APOE4 carrier status,
and time to last follow-up was constructed for cognitive
decline prediction. We then used an iterative approach,
first adding all analytes identified by the MOFA model
individually to the above reference model and selected
the model displaying the smallest Akaike information
criterion (AIC) value to select the best molecule to add
at each iteration. We repeated this process over succes-
sive iterations, adding a single analyte each time. Per-
formance of the models was analyzed by comparing area
under the curve (AUC) of the resulting ROC curves
using the DeLong method. No further improvements to
the AUC were observed after five iterations for both pre-
dictions. Confusion matrices to assess sensitivity and
specificity were calculated for all models.
Pathway enrichment
Proteins selected by the MOFA model were searched for
in the UniProt database [35], and their entry number
was then subsequently used within the Reactome
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database [36]. A separate over-representation analysis
was performed for each LF. This analysis used hypergeo-
metric distribution to determine which pathways and
biological reactions were over-represented within the
dataset. Over-represented pathways were then manually
grouped into broader ontology-based categories (Add-
itional file 3, Table S1).
Results
Cohort description
The clinical and demographical characteristics of the
participants included in this study are shown in Table 2.
Single-modality feature selection
Elastic-Net regression within each single ‘omics modality
identified 82 molecules associated with CSF “core” bio-
markers of AD pathology (i.e., Aβ1-42, Tau and P-Tau)
within the whole cohort (Tables 3, 4, and 5). Twenty out
of the thirty-seven proteins selected were correlated with
at least one CSF AD biomarker. Only two neuroinflam-
matory molecules displayed no correlation with CSF AD
biomarkers. Conversely, only two molecules at metabo-
lomics level and two lipids were correlated with CSF AD
biomarkers. Finally, total cysteine showed no correla-
tions (Additional file 3, Table S2). Strikingly, distinct
panels of CSF analytes were associated with either
Aβ1-42, or Tau and P-Tau, reflecting alterations of differ-
ent pathways in relation to amyloid pathology, neurode-
generation, and tau pathology, with very little overlap
(Fig. 1). Only protein 14-3-3 zeta/delta was associated
with all three biomarkers.
Overview of the MOFA model
In parallel, we trained a MOFA model on the whole co-
hort, to identify major dimensions of heterogeneity (la-
tent factors; LFs) responsible for the variance within the
cohort. This model identified five LFs that each ex-
plained a minimum of 2% variance in at least one of the
analyzed metabolic levels. Among these factors, LF1 and
LF2 were present in most multi-omics modalities, re-
vealing a broad participation to variance within the
cohort (Fig. 2). On the other hand, the remaining LFs
only captured variance across some modalities (three for
LF4 and LF5, two for LF3) and had a smaller contribu-
tion to overall variance. Across all LFs, the CSF AD bio-
markers accounted for 38.5%, proteins 39.8%, lipids
10.3%, neuroinflammation markers 10.3%, one-carbon
metabolites 9%, and other metabolites 3.7% of the vari-
ance contained within the cohort (Fig. 2). We next pro-
duced clustered heatmaps of the weight (i.e., the
Table 2 Study cohort
Whole cohort (n = 120) Control (n = 79) AD (n = 41) P value
Age (years) 70.37 ± 7.92 68.42 ± 8.23 74.15 ± 5.7 < 0.001
Sex (%, female) 64.2 67.1 58.5 0.354
Education (years) 12.37 ± 2.7 12.51 ± 2.7 12.10 ± 12.1 0.404
CDR-SoB 1.054 ± 1.6 0.456 ± 0.9 2.20 ± 2.0 < 0.001
MMSE 26.94 ± 3.08 27.85 ± 2.28 25.15 ± 3.71 < 0.001
P-Tau/Aβ1-42 ratio 0.088 ± 0.082 0.048 ± 0.127 0.165 ± 0.104 < 0.001
APOEε4 carrier (%) 29.6 17.7 56.1 < 0.001
Characteristics of the study cohort. Mean values ± standard deviation are presented. Per definition, participants within the AD group all presented a positive AD
CSF biomarker profile, defined by a P-tau/Aβ1-42 ratio > 0.0779. P value was obtained from t test for continuous variables or chi-square statistics for sex




Monocyte chemoattractant protein-1 − 78.6254
Proteomics
Spermine synthase 109.3853
WAP four-disulfide core domain protein 2 93.78915
Ephrin-B2 72.52614
Neuroendocrine convertase 2 55.25737
WAP four-disulfide core domain protein 1 42.96994




Sodium/potassium-transporting ATPase subunit alpha-2 17.62631
von Willebrand factor 17.59776
Mast/stem cell growth factor receptor kit 17.49956




Monocyte chemoattractant protein 1 −12.5945
SPARC related modular calcium binding 1 − 186.61
14-3-3 protein zeta/delta − 230.535
Analytes within the whole cohort with a significant association with CSF Aβ1-42
sorted by decreasing absolute association strength within each modality. For
each analyte, the coefficient obtained by Elastic-Net regression is shown
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Soluble fms-like tyrosine kinase 1 473.9178
Il-15 173.1296
Soluble vascular cell adhesion molecule-1 159.6389
Soluble intracellular cell adhesion molecule-1 90.9487
Monocyte chemoattractant protein-1 41.9127
Proteomics
14-3-3 protein zeta/delta 283.67
brain abundant membrane attached signal protein 1 107.72
SPARC related modular calcium binding protein 1 64.03
Neuromodulin 55.50
Fructose-biphosphate aldolase A 52.77
Neurofilament medium polypeptide 49.02
Transgelin-3 31.42
Secreted-frizzled-related protein 4 − 1.86
Chondroadherin − 7.99
Dynein heavy chain 10, axonemal − 11.34
Glia-derived nexin − 13.09
A-kinase anchor protein 11 − 18.52
Reelin − 18.86
Augurin − 43.98
Spectrin beta chain, non-erythrocytic 1 − 52.34
Sialate O-acetylesterase − 56.71
Proline-rich acidic protein 1 − 80.54
Fibromodulin − 84.41
Cathepsin D − 144.10
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association of an individual molecule with the LF) of
each analyte across different LFs (Fig. 3a–e) revealing
specific patterns of associations between analytes within
each analyzed multi-omic level and LFs. For example, a
subset of proteins with a negative association with LF1
have a positive association with LF2 (Fig. 3a) and mole-
cules within the one-carbon metabolism are differentially
associated with LF1 and LF2 (Fig. 3c). These patterns
suggest groups of molecules interacting together with
specific effects on LFs through common pathways. Be-
cause only three CSF core AD biomarkers were mea-
sured, we did not produce heatmaps to analyze the
association of Aβ1-42, Tau and P-Tau with these five LFs,
but rather, we inspected their absolute individual
loadings across all LFs (Fig. 4). This revealed that indi-
vidual CSF AD biomarkers had different contributions
across the identified LFs. CSF Tau and P-Tau levels were
strongly associated with LF1, LF2, and LF3, while Aβ1-42
was the main contributor to variance among the CSF
AD biomarkers to LF4 and LF5 indicating that these lat-
ter LFs were associated with amyloid pathology and the
former with tau pathology and neurodegeneration.
Individual analyte contributions to LFs
We next addressed the contribution of individual mole-
cules to variance within the cohort and how these mole-
cules aligned with CSF AD biomarkers. We selected
analytes with absolute normalized loadings > 0.8 within
any given LF derived from the MOFA model. This ap-
proach selected 37 proteins, 7 neuroinflammatory
markers, 3 one-carbon metabolites, 5 lipids, and 7 other
metabolites (not counting analytes selected in multiple
LFs) that contributed the most to variance within the co-
hort (Table 6). We next investigated the relationship be-
tween the identified analytes and the expression levels of
CSF AD biomarkers in the relevant LFs. We have shown
that the LFs are differentially associated with the individ-
ual CSF AD biomarkers. Molecules selected within each
LF are therefore associated with the CSF AD biomarkers.
Indeed, twenty out of thirty-seven proteins were corre-
lated with at least one CSF AD biomarker. Only two
neuroinflammatory molecules displayed no correlation
with CSF AD biomarkers. Conversely, only two mole-
cules at metabolomics level and two lipids were corre-
lated with CSF AD biomarkers. Finally, in one-carbon
metabolism, total cysteine showed no correlations (Add-
itional file 3, Table S2). As they were selected by the
MOFA model, these molecules are part of LFs who have
an effect on the variance within the cohort. By consider-
ing which LF they were selected from, we can infer that
they are part of an interacting set of analytes who is as-
sociated with changes in CSF AD biomarkers. For ex-
ample, despite showing no correlations with any CSF
AD biomarker, total cysteine is selected by our MOFA
model in LF1, LF2, and LF5. Because these LFs have
strong associations with Tau, P-Tau, and Aβ1-42 (Fig. 4),
total cysteine is related to a pathway or group of inter-
acting molecules in these LFs that together are associ-
ated with the markers of core AD pathology. Kininogen-
1 (KNG1) also displayed no correlation with CSF AD
biomarker, but we can infer it is part of a group of
Table 4 Analytes associated with CSF Tau (Continued)
Coeff.
Insulin-like growth factor-binding protein 7 − 169.27
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 − 213.32
Analytes within the whole cohort with a significant association with CSF Tau sorted by decreasing absolute association strength within each modality. For each
analyte, the coefficient obtained by Elastic-Net regression is shown. S56 and S62 represent different unidentified metabolites
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SPARC-related modular calcium binding 1 4.388161
Brain abundant membrane attached signal protein 1 4.028155
Neuromodulin 1.626098
Thymosin beta-10 1.291504
14-3-3 protein zeta/delta 1.10139
Pyruvate kinase PKM 0.189499
Analytes within the whole cohort with a significant association with CSF P-Tau
sorted by decreasing absolute association strength within each modality. For
each analyte, the coefficient obtained by Elastic-Net regression is shown. S56,
S59 and S61 represent different unidentified metabolites
Clark et al. Alzheimer's Research & Therapy           (2021) 13:71 Page 7 of 19
molecules associated with Tau and P-Tau, since it was
selected in LF2. In some cases, the MOFA model re-
vealed supplementary associations. For example, choles-
teryl ester SE 27:1 16:0 showed no correlations with
Aβ1-42 and strong correlations with both Tau and P-
Tau. This lipid was selected by our MOFA model in
LF4, however, suggesting it is part of an interactome
with a strong association with Aβ1-42.
Cross-modality interactions
Some of the identified LFs only contain a subset of the
tested modalities (Fig. 2). For instance, one-carbon me-
tabolism and metabolomics were only weakly associated
with LF3 and LF4, whereas lipidomics was nearly absent
from LF3 and LF5. Therefore, the contribution of indi-
vidual LFs to total variance results from a specific com-
bination of the different ‘omics modalities. In addition,
individual molecules also presented different patterns of
association across LFs. For example, a subset of lipids,
including PC 32:0, PC 34:1, LPA 18:3, and TAG 54:3,
had a strong positive association with LF2 and a weak
negative association with LF4. Since LF2 was associated
with all tested modalities (Fig. 2), this indicates these
analytes interact within multiple biological pathways and
could be within a hub of metabolic changes. Further-
more, LF2 is associated with both Tau and P-Tau indi-
cating neurodegeneration and tau pathology could
therefore relate to a more general metabolic alteration.
This is supported by the association of PC 32:0 with tau
pathology in single ‘omics. In contrast, LF4 is strongly
associated with amyloid pathology and it is only associ-
ated with changes in lipids and proteins (in addition to
CSF AD biomarkers). Therefore, only a subset of lipids
directly interacts with amyloid pathology. Taken to-
gether, these results show that the different aspects of
AD pathology derive from fundamentally different bio-
logical pathways and alterations.
Prediction of AD pathology and cognitive decline using
MOFA-selected molecules
In addition to associations with CSF biomarkers of AD
pathology, we found associations with AD reported in
the literature for 37 out of 58 metabolites selected by
our MOFA model (Table 6). Also, 29 of the selected
proteins and 5 lipids correlated with either baseline
CDR-SoB score or MMSE score Additional file 3, Table
S3), while,14 of the selected proteins were associated
with the presence of cognitive impairment at baseline in
regression models (Additional file 3, Table S4). There-
fore, in order to confirm a posteriori the importance of
the molecules with high weights selected from LFs
within the MOFA model, we evaluated their ability to
predict either cerebral AD pathology or global cognitive
decline. The model for AD prediction selected four
Fig. 1 Venn diagram of associations with CSF core AD biomarkers. Venn diagram of associations of analytes obtained by regression models with
CSF core AD biomarkers. Number of molecules identified as well as those shared between biomarkers is shown. The full list of associated
molecules is presented in Tables 3, 4, and 5
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analytes: protein 14-3-3 zeta/delta, clusterin, interleukin-
15, and transgelin-2, that together improved the AUC of
the ROC curve when compared to the reference model
(Fig. 5a, p value = 0.002). In addition, both sensitivity
(0.71 to 0.86) and specificity (0.87 to 0.96) were im-
proved from the reference model. Further, adding to a
reference model for the prediction of cognitive decline,
four selected molecules, protein 14-3-3 zeta/delta, clus-
terin, cholesteryl ester 27:1 16:0, and monocyte chemo-
attractant protein-1, improved its AUC (Fig. 5b, p
value = 0.0047). This also improved sensitivity (0.56 to
0.80) but not specificity (0.89 to 0.88). For both predic-
tion of cerebral AD and of cognitive decline, the
addition of single molecules to the reference models did
not improve prediction (data not shown).
Metabolic pathway enrichment
Using the Reactome database and coarse-grain onto-
logical categories (See the “Methods” section and Add-
itional file 3, Table S1), we investigated which biological
pathways were over-represented within each LF for the
proteomic modality. Other modalities were not analyzed
in this fashion since they were selected a priori to repre-
sent distinct metabolic pathways (one-carbon metabol-
ism and inflammatory markers) or did not contain
enough molecules to conduct pathway analysis. Lipids
were also excluded from this analysis since our quantifi-
cation method did not allow to dissociate between dif-
ferent isoforms of compounds with the same chemical
formula. This approach revealed an overrepresentation
of the hemostasis (28.8%), immune response (20.8%),
and extracellular matrix signaling pathways (8.8%)
(Fig. 6).
Discussion
Here, we applied a multi-layered integrative approach to
disentangle sources of variance within a cohort of elderly
participants with normal cognition, mild cognitive im-
pairment, or mild AD dementia. We identified five
major dimensions of heterogeneity that together com-
prehensively explained the variance within the cohort
and were associated with core AD pathology. Further
analysis revealed multiple interactions between single
‘omics modalities, distinct multi-omics molecular
Fig. 2 Overview of the MOFA model. Overview of the trained MOFA model showing variance (R2) within the cohort explained by each modality
(top) and latent factors (LFs, bottom) from the trained MOFA model
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patterns differentially associated with amyloid aggrega-
tion, neurodegeneration, and tau hyperphosphorylation,
and novel molecules associated with cognitive impair-
ment. Specific signatures of four molecules improved
the accuracy of both AD and cognitive decline predic-
tion. Additionally, pathway enrichment showed over-
representation of the hemostasis, immune response and
extracellular matrix signaling pathways in association
with AD.
Single modality feature selection
We first used Elastic-net regression, to identify mole-
cules associated with individual biomarkers of CSF AD
pathology without considering any possible interactions
between different ‘omics modalities. This approach iden-
tified several proteins (SPARC-related modular calcium-
binding protein 1, brain acid soluble protein 1, neuro-
modulin, pyruvate kinase PKM, thymosin beta-10, 14-3-
3 protein zeta/delta, and fructose-bisphosphate aldolase
A) in strong accordance with recent studies of the AD
CSF proteome [24, 65]. The zeta/delta isoform of protein
14-3-3 was associated with Aβ1-42, Tau, and P-Tau
levels. This apoptosis inhibitor, one of the most abun-
dant proteins in the brain, was previously found to ex-
hibit altered levels in AD and modulate AD risk [66, 67].
We also identified associations of neurofilament medium
polypeptide with Tau levels and of reelin with Aβ1-42
and Tau levels. Both these molecules have previously
been associated with AD [68–70]. Regarding neuroin-
flammatory molecules, C-reactive protein and monocyte
chemoattractant protein-1 have previously been associ-
ated with AD, albeit in plasma [71]. In addition, we have
also previously shown that soluble intracellular cell ad-
hesion molecule-1 in CSF is associated with AD [30]. At
metabolite level, we identified 10 molecules in CSF asso-
ciated with Tau and P-Tau, which differ from the blood
biomarkers associated with AD identified in a recent
study in a large sample [72]. Overall, our approach iden-
tified more molecules associated with AD pathology as
compared to previous studies. A likely source of
Fig. 3 Clustering of loadings across latent factors. Heatmaps of hierarchical clustering of the measured loadings across in LFs for data obtained
from proteomics (a), neuroinflammation markers (b), one-carbon metabolism (c), metabolomics (d), and lipidomics (e) showing clusters of
analytes along the X-axis and the association of each individual analyte with each LF (shown on the Y-axis). Note the distinct pattern within each
LF. Color scale indicates both the direction and strength of relative associations
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differences is the use of Elastic-Net regression in the
current study which eliminates saturation of the regres-
sion and could therefore identify more associations. On
the other hand, our approach did not identify any lipids
or metabolites associated with Aβ1-42 levels. It is possible
that it is not the individual levels of these molecules that
are associated with Aβ1-42 levels, but rather lipidomic
pathway alterations where associations of individual
lipids are weak but the overall pathway in which they
are embedded is strongly associated with amyloid
pathology.
Heterogeneity within the cohort
An important strength of our study is to consider all in-
teractions between multiple biological levels and their
associations with the heterogeneity within the cohort.
This was achieved by training a MOFA model on the
multi-omics dataset which has the advantage of not giv-
ing any additional analysis weight to the established CSF
biomarkers of core AD pathology while also reducing
the complexity of the data to better depict the sources of
variation. This revealed proteomic measures and CSF
core AD biomarkers as the main contributors to the
variance with both having very similar contributions to
variance, albeit from 768 proteins versus 3 AD bio-
markers. The biomarker contribution was expected as
our sample contains a large proportion of participants
with AD, each displaying CSF AD biomarkers signifi-
cantly different from subjects without AD. The large
contribution of proteomics to variance could derive, at
least in part, from the fact that protein expression levels
reflect the effects of different environments, life style,
health conditions, and genetic backgrounds; all factors
potentially affecting protein expression and regulation
[73]. Nonetheless, MOFA analysis identified 21 proteins
with previously reported association to AD, suggesting,
along with the associations with AD biomarkers ob-
served here, that protein contribution to variance is
linked to AD pathology. These findings further show
that the MOFA approach can accurately disentangle the
inter-individual heterogeneity driven by AD pathology
and differentiate between individual (i.e., not repeated in
Fig. 4 Loadings of CSF AD biomarkers. Normalized loadings of CSF AD biomarkers shown on the X-axis across the five latent factors of the
trained MOFA model. Positive or negative signs indicate the relative direction of the CSF AD biomarkers with the associated latent factor. Note
that signs are relative within a single latent factor for biomarker weights
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Table 6 Analytes associated with latent factors
LF Analyte Full name Entry# Previously reported AD association
Proteomics
1 NRN1 Neuritin isoform 1 precursor Q9NPD7
1 SMS Spermine synthase P52788 Yes [37]
1 NXPH4 Neurexophilin-4 O95158
1 LTBP1 Latent-transforming growth factor beta-binding protein 1 Q14766
1 CLUS Clusterin P10909 Yes [38]
1 NPDC1 Neural proliferation differentiation and control protein 1 Q9NQX5
1 PNOC Prepronociceptin Q13519
1 DYL2 Dynein light chain 2, cytoplasmic Q96FJ2
1 PDGFB Platelet-derived growth factor subunit B P01127 Yes [39]
1 SAP3 Sphingolipid activator protein 3 P17900
1 MT1E Metallothionein-1E P04732 Yes [40]
1 PCSK1 Neuroendocrine convertase 1 P29120 Yes [41]
1 TAGL Transgelin-2 P37802 Yes [42]
1 MT3 Metallothionein-3 P25713 Yes [40]
1 LY6H Lymphocyte antigen 6H O94772
2 SAMP Spindle-associated membrane protein 1 Q5SNT2
2 VTNC Vitronectin P04004 Yes [43]
2 KNG1 Kininogen-1 P01042
2 FETUA Alpha-2-HS-glycoprotein P02765 Yes [44]
2 HELZ Probable helicase with zinc finger domain P42694
2 PLMN Plasminogen P00747 Yes [45]
2 PGRP2 N-acetylmuramoyl-L-alanine amidase Q96PD5
2 AFAM Afamin P43652 Yes [44]
2 ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 P19827 Yes [46]
2 CO8B Complement component C8 beta chain P07358 Yes [47]
2 FIBA Fibrinogen alpha chain P02671 Yes [48]
2 CO6 Complement component C6 P13671 Yes [47]
2 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 Yes [46]
3 EPDR1 Mammalian ependymin-related protein 1 Q9UM22
3 SIAE Sialate O-acetylesterase Q9HAT2
4 X1433Z 14-3-3 protein zeta/delta P63104 Yes [49]
4 S10A6 Protein S100-A6 P06703 Yes [50]
4 PRDX6 Peroxiredoxin-6 P30041 Yes [51]
5 VTM2A V-set and transmembrane domain-containing protein 2A Q8TAG5
5 S10A6 Protein S100-A6 P06703 Yes [50]
5 CMGA Chromogranin-A P10645 Yes [52]
5 ZP2 Zona pellucida sperm-binding protein 2 Q05996
5 SLIK1 SLIT and NTRK-like protein 1 Q96PX8 Yes [53]
Neuroinflammation
1 sVCAM-1 Circulating vascular cell adhesion molecule-1 P19320 Yes [54]
1 IL-15 Interleukin-15 P40933 Yes [54]
1 sICAM-1 Soluble intracellular adhesion molecule-1 P05362 Yes [54]
2 SAA Serum amyloid A P0DJI8 Yes [55]
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the dataset) and cohort heterogeneity (i.e., underlying
changes in many participants). Conversely, the metabo-
lomic dataset was only responsible for a small amount of
the cohort heterogeneity (3.7%), a possible explanation
being that it represents individual heterogeneity for the
most part caused by the environment, disease processes,
or nutritional habits. This low contribution of metabolo-
mics to variance could also result from the lower dimen-
sionality of the metabolomics dataset as molecules
within had lower concentrations compared to molecules
in the other modalities. Yet, despite this low level of
variance, our model was able to correctly retrieve metab-
olites previously reported in association with AD, under-
lining the sensitivity of the model. This is further
supported by the ability of our approach to determine a
four-molecule signature that improves the prediction of
AD pathology.
Associations between LF and specific aspects of AD
pathology
Our analysis revealed that LFs 1–3 were primarily asso-
ciated with neuronal injury while LF4 and LF5 were
mainly associated with amyloid pathology. In addition,
both Tau and P-Tau were negatively associated with
LF3, while Aβ1-42 presented a positive, albeit weaker, as-
sociation with this same LF. Conversely, Tau and P-Tau
were positively while Aβ1-42 was strongly negatively as-
sociated with LF4. Whether the LF3 and LF4, that show
Table 6 Analytes associated with latent factors (Continued)
LF Analyte Full name Entry# Previously reported AD association
2 PIGF_1R Insulin-like growth factor 1 receptor P08069 Yes [56]
3 PIGF_1R Insulin-like growth factor 1 receptor P08069 Yes [56]
4 IL-16 Interleukin-16 Q14005 Yes [57]
5 MCP-1 Monocyte chemoattractant protein-1 P13500 Yes [54]
5 PIGF_1R Insulin-like growth factor 1 receptor P08069 Yes [56]
One-carbon metabolism
1 MTHF 5-methyltetrahydrofolate 20,612 Yes [58]
1 SAH S-adenosyl-L-homocysteine 16,680 Yes [59]
2 CYST Total cysteine 15,356 Yes [60]
3 SAH S-adenosyl-L-homocysteine 16,680 Yes [59]
4 CYST Total cysteine 15,356 Yes [60]
5 CYST Total cysteine 15,356 Yes [60]
Metabolomics
1 N/A Glycoproteins 17,089 Yes [61]
2 N/A Alanine 16,449 Yes [62]
2 N/A Valine 27,266
2 N/A Glycoproteins 17,089 Yes [61]
3 N/A Inositol 24,848
4 N/A Glycoproteins 17,089 Yes [61]
5 N/A Formic acid 30,751
5 S69 Unidentified metabolite N/A N/A
5 N/A Acetoacetic acid 15,344 Yes [63]
Lipidomics
1 PC 32:0 1,2-Dihexadecanoyl-sn-glycero-3-phosphocholine N/A Yes [64]
2 SE 27:1 18:2 Cholesteryl ester N/A
3 PC 32:0 1,2-Dihexadecanoyl-sn-glycero-3-phosphocholine N/A Yes [64]
4 SE 27:1 18:2 Cholesteryl ester N/A
4 SE 27:1 20:4 Cholesteryl ester N/A
4 SE 27:1 16:0 Cholesteryl ester N/A
5 LPG 20:1 1-(11Z-eicosenoyl)-glycero-3-phospho-(1′-sn-glycerol) N/A
CSF biomolecules significantly associated with the LFs within the MOFA model and whether they have been previously associated with AD. Entry# denotes the
analyte identifier within the UniProt database (for proteomics and neuroinflammation) or ChEBI database (for other analytes)
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congruent relationships with amyloid aggregation, tau
pathology and neurodegeneration, may be particularly
relevant for AD remains to be confirmed. The finding
that the zeta/delta isoform of protein 14-3-3, selected in
LF4, is associated with all AD CSF biomarkers along
with its contribution to predictive models of cerebral
AD is in line with the hypothesis that these LFs are in-
volved in AD pathology.
Interactions between LFs and ‘omics modalities
Besides the identification of molecular profiles and
metabolic pathways alterations associated with AD, our
approach offers the unique ability to disentangle how
components of individual LFs interact with each other
to explain variance within the cohort. This not only re-
veals specific interactions between subsets of molecules
and particular metabolic pathways but also offers a
unique view into how multiple biological levels interact
in the context of AD pathology and how they are related
to specific aspects of the pathology. In addition, this ap-
proach has the advantage of not being biased towards
any known biological alteration of AD pathology or
giving any particular weight to a specific molecule or
metabolic pathway. In the context of AD, this could lead
to the identification of pathways and alterations not dir-
ectly related to the core features of AD pathology, better
reflecting the heterogeneity of the disease. The presence
of clusters within each LF also suggests specific groups
of molecules interacting with each other across LFs. A
more comprehensive analysis of the role of these clusters
of analytes may be addressed in future studies.
Novel associations uncovered by the MOFA model
The MOFA model uncovered additional relationships
not revealed by other analysis exploration paradigms
since it does not only consider molecules from one
modality but the whole dataset from different ‘omics.
These additional findings may result from the down-
stream effects of these molecules or from interactions
with other modalities. These include the association
of total cysteine with CSF Aβ1-42, Tau, and P-Tau or
the association of kininogen-1 (KNG1) with Tau and
P-Tau. While cysteine was previously linked with AD
[60], KNG-1 has been associated with other
Fig. 5 Clinical predictions. Binary logistic regression models to improve clinical predictions. a ROC curves and AUCs for the reference model
including APOE status (green) and the final prediction model of AD pathology (red) obtained after addition of four analytes (14-3-3 zeta/delta,
clusterin, interleukin-15, and transgelin-2) selected by the MOFA model. b Confusion matrix of the final prediction model of AD. c ROC curves
and AUCs for the reference model including APOE status (green) and the final prediction model of cognitive decline (red) obtained after addition
of four analytes (14-3-3 zeta/delta, clusterin, cholesteryl ester 27:1 16:0 and monocyte chemoattractant protein-1) selected by the MOFA model. d
Confusion matrix of the final prediction model of cognitive decline
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neurodegenerative disorders [74], but its association
with AD, and in particular tau pathology and neur-
onal injury, is novel. The MOFA model also identi-
fied molecules previously associated with cognitive
impairment, such as dynein light-chain 2, cytoplas-
mic (DYL2), and neurexophilin-4 (NXPH4). Both
were associated with LF1 and with cognitive impair-
ment. DYL2 is thought to regulate dynein function
[75] and maintain cytoskeletal structure, therefore
regulating synaptic function [76]. NXPH4 structurally
resembles neurexophilin-1, an α-neurexin ligand,
which promotes adhesion between dendrites and
axons and modulates specific cerebellar synapses and
motor functions [77]. Altered levels of these proteins
may therefore be associated with neurodegeneration
processes and related to cognitive impairment in
AD. Another novel analyte we identified is the cho-
lesteryl ester SE 27:1 16:0. While links between
phosphatidylcholine metabolism and AD in general
[78] and PC 32:0 in particular [64] have been previ-
ously reported, to our knowledge, cholesteryl esters
have not previously been associated with AD path-
ology. In our MOFA model, this cholesteryl ester
was strongly correlated to LF4, suggesting a role in
amyloid pathology. These molecules were also asso-
ciated with cognitive performance as measured by
MMSE. Together, these results demonstrate the cap-
acity of integrative multi-omics to provide additional
insights into the relationship of molecular alterations
with specific aspects of the AD pathology.
Prediction of AD pathology and cognitive decline using
MOFA-selected molecules
Molecular signatures associated with AD or predictive of
cognitive decline were derived from our model. Both sig-
natures contain four molecules each, taken from mul-
tiple biological levels and significantly improved
prediction performance when added to reference
models. The four molecules from the combination re-
lated to AD pathology have each been associated with
AD previously [38, 42, 49, 54]. From the molecule com-
bination that improved prediction of cognitive decline,
three molecules have been linked to cognitive decline in
previous reports [79–81], while one molecule, choles-
teryl ester 27:1 16:0 was not. Both signatures also share
two common molecules, protein 14-3-3 zeta/delta and
clusterin, suggesting these belong to common biological
pathways both associated with AD and relevant for cog-
nitive decline. Cholesteryl ester 27:1 16:0 and monocyte
chemoattractant protein-1 may indicate pathway alter-
ations without a strong and direct link to core AD path-
ology but having impact on the rapidity of cognitive
decline. These predictive models also demonstrate the
ability of this approach to identify biomarker candidates
for both AD pathology and cognitive decline. Additional
investigation and validation in independent cohorts is
required before possible clinical use.
Infer pathway relationships with AD pathology
One important strength of the MOFA approach is that
it enables addressing the relationship between multiple
Fig. 6 Pathway enrichment. Pathway enrichment analysis of identified proteins across LFs and overall. The number of over-represented categories
within each LF (expressed as a percentage) as well as across all LFs is represented. NB: the low number of analytes associated with LF3 did not
allow for an enrichment analysis
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biological pathways and associate them with sources of
variance (i.e., LFs). Using over-representation of meta-
bolic pathways, we were able to show that individual
LFs, and the main related pathological aspects of AD
(i.e., amyloid aggregation, neurodegeneration and tau
pathology) are associated with distinct pathways.
Hemostasis and immune response were the most over-
represented. Only the immune response was associated
with all LFs in which individual pathways could be iden-
tified. LF1 and LF2 presented a significant enrichment in
biomolecules implicated in hemostasis, suggesting an as-
sociation between this pathway and neuronal injury, and
tau pathology. While an association between hemostasis
and amyloid pathology pathway was previously described
[82], in particular related to expression of amyloid pre-
cursor protein and release of Aβ [83], there have also
been recent reports of an association between Tau and
hemostasis [84]. Molecules involved in the extracellular
matrix were significantly enriched in LF2, also suggest-
ing an association with tau-related pathology, in line
with previous reports [85]. However, this pathway was
not detected within LF1 or other LFs. We therefore
hypothesize that the molecules involved are those pre-
senting a specific pattern of association with LF2, such
as PC 32:0, PC 34:1, LPA 18:3, and TAG 54:3. Neuronal
function was confined to associations with LF5, suggest-
ing little variation and differences in signal transmission
and synaptic function across the cohort since this LF
only explained 8% of the variance. Nonetheless, this re-
sult suggests an association with amyloid pathology,
which is in accordance with previous findings of amyloid
being released in an activity-dependent fashion from
neurons and modulating synaptic function and plasticity
[86, 87]. Overall, the enriched metabolic pathways sug-
gest that AD pathology affects not only pathways related
to neuronal biological systems but is linked to a broader
spectrum of metabolic dysfunctions.
Limitations
A limitation of this study is the different amounts of
analytes measured by individual quantification method
(i.e., > 500 proteins measured vs. < 100 metabolites/lipids
for example) resulting from methodological differences.
This approach prevents measuring the relative import-
ance of the analytes or their combinations but allows the
identification of altered pathways or molecular signa-
tures from different modalities. Furthermore, since the
data entered in the MOFA analyses did not include in-
formation regarding clinical stages, stage-specific alter-
ations have not been addressed. Also, the inclusion of
some targeted analysis results in the multi-omics models
may be considered as a limitation. While the proteomic
and lipidomic dataset are hypothesis-free measurements
and the study could be limited to this data, we chose to
include further available modalities. In particular, we
considered neuroinflammation and one-carbon metabol-
ism given their previously reported associations with AD
and relevance for brain metabolism. However, the repli-
cation of these and other previously reported associa-
tions in our MOFA model along with the ability of the
MOFA selected marker combinations to improve predic-
tion of AD and of cognitive decline support the validity
of the new findings revealed in the present study.
Conclusions
Here, applying integrative multi-omics in AD, we have
identified five axes of variation within a cohort of indi-
viduals with normal cognition or with cognitive impair-
ment. These five LFs were associated with different
aspects of the core AD pathology. We confirmed several
previously reported associations with AD and identified
new molecular patterns interrelated within each LF.
Additionally, we identified molecular biomarker signa-
tures improving the diagnosis of AD pathology and the
prediction of future cognitive decline. Furthermore,
using pathway enrichment analysis, we have revealed
metabolic pathways represented within single LFs and
explored specific relationships with markers of amyloid
pathology, neuronal injury, and tau hyperphosphoryla-
tion. These findings demonstrate the added value of in-
tegrative multi-omics analysis to uncover interrelated
pathway alterations in AD and its ability to identify bio-
marker combinations that may be used in clinical prac-
tice. This is relevant for the development of both
personalized diagnosis and tailored therapeutic interven-
tions in AD.
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